Given the paradigm of anti-insulin resistance in therapies for metabolic syndrome, there has been considerable interest in adiponectin (APN), an adipocyte-derived sensitizer of insulin receptor signaling. In contrast to hypoadiponectinemia in metabolic syndrome, evidence suggests that Alzheimer’s disease (AD) and other diseases, including chronic heart failure (CHF) and chronic kidney disease (CKD), are characterized by hyperadiponectinemia as well as the APN/obesity paradoxes, indicating that a decrease in APN might also be beneficial for these diseases. Thus, distinct from metabolic syndrome, it is anticipated that APN receptor antagonists rather than agonists might be effective in therapy for some chronic diseases.

鉴于代谢综合征治疗中抗胰岛素抵抗的范式，人们对脂联素 (APN) 产生了相当大的兴趣，脂联素是一种脂肪细胞衍生的胰岛素受体信号传导增敏剂。与代谢综合征中的低脂联素血症相比，有证据表明阿尔茨海默病 (AD) 和其他疾病，包括慢性心力衰竭 (CHF) 和慢性肾病 (CKD)，以高脂联素血症以及 APN/肥胖悖论为特征，表明APN 的减少也可能对这些疾病有益。因此，与代谢综合征不同，预计 APN 受体拮抗剂而不是激动剂可能对某些慢性疾病的治疗有效。